A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Ability to understand and sign a written informed consent documen；
• At the date of signing ICF, 18 \
⁃ 70 years old, male or female；
• Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
• Positive mesothelin expression;
• At least one measurable lesion at baseline per RECIST version 1.1；
• The expected survival time is more than 12 weeks;
• ECOG 0-1 points;
• Adequate organ functions.
Locations
Other Locations
China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING
Tianjin
Contact Information
Primary
Jihui Hao, Ph.D
haojihui@tjmuch.com
+86-02223340123
Time Frame
Start Date: 2024-12-25
Estimated Completion Date: 2039-12-24
Participants
Target number of participants: 21
Treatments
Experimental: CHT102 infusion
CHT102 will be dosing by arterial infusion.
Related Therapeutic Areas
Sponsors
Collaborators: Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Leads: Tianjin Medical University Cancer Institute and Hospital